Semaglutide vs Liraglutide: Complete Comparison for Weight Loss & Diabetes

Both semaglutide and liraglutide are GLP-1 receptor agonists approved for weight loss and diabetes management, but they're not interchangeable. These medications have different mechanisms of action, dosing schedules, side effect profiles, and costs. This detailed comparison helps you understand the key differences and decide which medication might be best suited to your needs.

What They Have in Common

Both semaglutide (Ozempic, Wegovy) and liraglutide (Victoza, Saxenda) are GLP-1 receptor agonists—medications that mimic glucagon-like peptide-1, a hormone that regulates appetite and blood sugar. Both medications:

• Reduce appetite and promote satiety
• Slow gastric emptying (how quickly food leaves the stomach)
• Improve insulin secretion in response to meals
• Have similar side effect profiles (nausea, GI disturbances)
• Require weekly or daily injections
• Show significant weight loss benefits

However, the devil is in the details. Several fundamental differences affect efficacy, tolerability, and cost.

Clinical Efficacy: Weight Loss Results

Semaglutide Weight Loss Data

Semaglutide has been evaluated in multiple large clinical trials:

STEP 1 Trial (52 weeks with semaglutide 1.0mg)

• Baseline weight: 105 kg (231 lbs)
• Weight loss: 10.2% of body weight (4.6 kg / 10.1 lbs)
• Placebo weight loss: 2.6%
• Net difference: 7.6% greater than placebo

STEP 2 Trial (68 weeks with semaglutide 1.0mg)

• Weight loss: 10.3% of body weight
• Placebo weight loss: 3.0%
• Net difference: 7.3% greater

STEP 3 Trial (68 weeks with semaglutide 2.4mg)

• Weight loss: 17.4% of body weight (18.5 kg / 40.8 lbs)
• Placebo weight loss: 2.4%
• Net difference: 15.0% greater
• This is the dose used in Wegovy for weight loss

Liraglutide Weight Loss Data

Liraglutide has been evaluated for weight loss in the SCALE trial series:

SCALE Obesity and Prediabetes Trial (56 weeks with liraglutide 3.0mg)

• Weight loss: 8.4% of body weight (6.0 kg / 13.2 lbs)
• Placebo weight loss: 2.8%
• Net difference: 5.6% greater than placebo

SCALE Diabetes Trial (56 weeks with liraglutide 1.8mg)

• Weight loss: 6.2% of body weight
• Placebo weight loss: 2.0%
• Net difference: 4.2% greater

Real-World Effectiveness

While clinical trials show semaglutide's superiority, real-world data from electronic health records and patient registries shows:

• Average semaglutide weight loss: 15-22% of body weight over 1 year (varies with dose and adherence)
• Average liraglutide weight loss: 8-12% of body weight over 1 year
• Variability: Some users lose significantly more or less than average, influenced by starting weight, adherence, diet, and exercise

Dosing Schedules and Protocols

Semaglutide Dosing

Dosing Schedule (Weekly injections)

| Week | Dose | |---|---| | Week 1-4 | 0.25mg weekly | | Week 5-8 | 0.5mg weekly | | Week 9-12 | 1.0mg weekly | | Week 13+ | 1.7-2.4mg weekly (maintenance) |

Key characteristics:

• Weekly subcutaneous injection (abdomen, thigh, or upper arm)
• Dose escalation occurs every 4 weeks
• Most users reach therapeutic effect at 1.0mg, but higher doses (1.7-2.4mg) produce greater weight loss
• Full dose escalation takes 16-20 weeks

Liraglutide Dosing

Dosing Schedule (Daily injections)

| Week | Dose | |---|---| | Week 1 | 0.6mg daily | | Week 2 | 1.2mg daily | | Week 3 | 1.8mg daily | | Week 4+ | 2.4mg or 3.0mg daily (maintenance) |

Key characteristics:

• Daily subcutaneous injection (abdomen, thigh, or upper arm)
• Dose escalation occurs weekly (faster than semaglutide)
• Maximum approved dose for weight loss (Saxenda): 3.0mg daily
• Full dose escalation takes 4 weeks

Convenience and Adherence

The dosing frequency difference significantly impacts real-world adherence:

Semaglutide Advantages

• Weekly injections: Only 4 injections monthly vs. 30 for liraglutide
• Lower injection burden: Fewer syringes, smaller total volume injected annually
• Travel-friendly: Easier to manage injections while traveling
• Injection fatigue: Users report less needle-related anxiety with weekly dosing

Liraglutide Disadvantages

• Daily injections: Requires daily adherence (like insulin)
• Higher injection burden: 365 injections yearly
• Missed doses: Even one missed daily dose can reduce efficacy
• Injection-related complications: Higher risk of lipohypertrophy (fatty deposits at injection sites)

Real-world impact: Studies show adherence rates of 85-90% for weekly semaglutide vs. 70-75% for daily liraglutide over 12 months. The weekly schedule's simplicity translates directly to better long-term results.

Side Effects Comparison

Common Side Effects by Medication

| Side Effect | Semaglutide | Liraglutide | Notes | |---|---|---|---| | Nausea | 25-40% | 20-35% | Semaglutide slightly higher at high doses | | Vomiting | 10-20% | 10-15% | Similar incidence | | Diarrhea | 15-25% | 15-20% | Comparable | | Constipation | 10-20% | 15-25% | Liraglutide slightly more common | | Abdominal pain | 5-15% | 8-12% | Similar | | Headache | 3-8% | 5-10% | Liraglutide slightly higher | | Fatigue | 5-10% | 3-8% | Similar |

Duration of Side Effects

Semaglutide

• Peak side effects: Weeks 1-2 after dose escalation
• Duration: Usually resolve within 1-2 weeks
• Tolerance builds quickly due to weekly dosing allowing acclimation time

Liraglutide

• Peak side effects: Daily injections mean continuous dosing
• Duration: Can persist longer; less "adaptation period" between doses
• Some users report persistent GI symptoms throughout treatment

Injection Site Reactions

Semaglutide

• 5-10% report mild injection site reactions
• Weekly injections allow site rotation more effectively
• Risk of lipohypertrophy is lower

Liraglutide

• 10-15% report injection site reactions
• Daily injections at same or nearby sites increase lipohypertrophy risk
• Requires systematic rotation across many sites to minimize complications

Cardiovascular Benefits

Both medications show cardiovascular benefits beyond weight loss:

Semaglutide Cardiovascular Data

SUSTAIN-6 Trial (56 weeks, diabetes patients)

• 26% reduction in major cardiovascular events
• 39% reduction in cardiovascular death
• 26% reduction in non-fatal MI or stroke

Liraglutide Cardiovascular Data

LEADER Trial (3.8 years, diabetes patients)

• 13% reduction in major cardiovascular events
• 22% reduction in cardiovascular death
• 13% reduction in non-fatal MI or stroke

Semaglutide's superiority in cardiovascular risk reduction mirrors its weight loss superiority.

Cost Comparison

Semaglutide Costs

Brand Name (Ozempic for diabetes, Wegovy for weight loss)

• Without insurance: $900-1,300 per month
• With insurance: $0-300 copay (varies widely)
• Patient assistance programs available (Novo Nordisk programs)

Generic/Compounded

• Compounded semaglutide: $150-400 per month
• Quality varies; requires vetting of compounding pharmacy

Liraglutide Costs

Brand Name (Victoza for diabetes, Saxenda for weight loss)

• Without insurance: $800-1,100 per month
• With insurance: $0-250 copay
• Patient assistance programs available (Novo Nordisk programs)

Generic/Compounded

• Generic not available yet (patent protection through 2026)
• Compounded options emerging but less common than semaglutide

Cost Breakdown per Injection

| Medication | Route | Cost per Dose | Doses/Year | Annual Cost | |---|---|---|---|---| | Semaglutide 2.4mg (brand) | Weekly | $180-250 | 52 | $9,360-13,000 | | Semaglutide (compounded) | Weekly | $30-75 | 52 | $1,560-3,900 | | Liraglutide 3.0mg (brand) | Daily | $25-35 | 365 | $9,125-12,775 | | Liraglutide (brand generic soon) | Daily | $15-25 | 365 | $5,475-9,125 |

Drug Interactions and Contraindications

Semaglutide

Contraindications:

• Personal or family history of medullary thyroid cancer (MTC)
• Multiple endocrine neoplasia syndrome type 2 (MEN2)
• Severe hypersensitivity to semaglutide

Drug Interactions:

• May slow absorption of oral medications (take 30+ minutes before injection if possible)
• Increased hypoglycemia risk with insulin or sulfonylureas (dose adjustment needed)
• No significant interactions with most other medications

Liraglutide

Contraindications:

• Same as semaglutide (MTC history, MEN2)
• Severe hypersensitivity to liraglutide

Drug Interactions:

• Similar to semaglutide
• Increased hypoglycemia risk with insulin or sulfonylureas
• Daily dosing means more consistent drug levels, less variation in interactions

Which Should You Choose?

Choose Semaglutide If:

1. Efficacy is your priority: You need maximum weight loss (especially if BMI greater than 35)
2. Convenience matters: You prefer one injection weekly vs. daily
3. Injection anxiety: You want fewer injections
4. Cost is a factor: Compounded semaglutide is significantly cheaper
5. You've tried liraglutide: Previous response to liraglutide inadequate
6. Cardiovascular risk reduction: You have existing cardiovascular disease (superior data)

Choose Liraglutide If:

1. Tolerability concerns: History of GI issues; liraglutide's slower absorption may be gentler
2. Moderate weight loss goal: Need 8-12% weight loss, not 15-20%
3. Cost and insurance: Brand generic available soon; may be cheaper with insurance
4. Needle phobia workaround: Can transition to oral semaglutide when available (not yet approved in US)
5. Diabetes is primary goal: Adequate for glycemic control; weight loss secondary

Switching Between Medications

If you start with one and wish to switch:

Semaglutide to Liraglutide

• Stop semaglutide, start liraglutide 0.6mg daily the next day
• Expect restart of GI side effects briefly
• Increased appetite as semaglutide clears (takes 1-2 weeks)

Liraglutide to Semaglutide

• Stop liraglutide, start semaglutide 0.25mg weekly
• Immediate appetite suppression increase
• Expect nausea during first 2-4 weeks as body adjusts to weekly dosing

Many clinicians recommend continuing the first medication for 12+ weeks before switching to ensure adequate trial, as both require time for optimization.

Future Developments

Semaglutide Evolution

• Oral semaglutide (Rybelsus) exists for diabetes but higher doses for weight loss are in development
• Combined semaglutide/finerenone (for kidney protection) in development
• Longer-acting formulations (monthly injections) under investigation

Liraglutide Evolution

• Oral liraglutide in development
• Generic versions launching 2026-2027 (significant cost reduction)
• Combination therapies with other agents in trials

The Bottom Line

Semaglutide's superior efficacy makes it the first-choice GLP-1 for most weight loss and diabetes patients. However, liraglutide remains an excellent option for those who:

• Tolerate daily injections
• Need adequate (but not maximal) weight loss
• Prefer lower cost long-term (especially once generics arrive)
• Have specific tolerability concerns with semaglutide

Work with your healthcare provider to discuss your specific goals, cost constraints, and medical history. Both medications represent remarkable advances in weight loss and metabolic health. The best medication is the one you'll use consistently and that aligns with your health objectives.

For tracking and optimizing your GLP-1 therapy—whether semaglutide or liraglutide—use PepTracked to log dose, weight, side effects, and health markers. Data-driven adjustment leads to better outcomes.